Ectopic expression of CDX2 in patients with AML
| Patient group . | Samples tested for CDX2 transcript, no. . | CDX2-positive samples, no. . | Positive samples, % . |
|---|---|---|---|
| NK, NPM1c+ | 45 | 40 | 89 |
| NK, NPM1c− | 26 | 23 | 88 |
| AML1-ETO | 24 | 12 | 50 |
| PML-RARα | 10 | 10 | 100 |
| MLL fusions | 6 | 3 | 50 |
| inv16 | 4 | 3 | 75 |
| Patient group . | Samples tested for CDX2 transcript, no. . | CDX2-positive samples, no. . | Positive samples, % . |
|---|---|---|---|
| NK, NPM1c+ | 45 | 40 | 89 |
| NK, NPM1c− | 26 | 23 | 88 |
| AML1-ETO | 24 | 12 | 50 |
| PML-RARα | 10 | 10 | 100 |
| MLL fusions | 6 | 3 | 50 |
| inv16 | 4 | 3 | 75 |
Percentage of patients positive for CDX2.
NK indicates normal karyotype.